Ultragenyx Pharmaceutical (RARE) Other Non Operating Income (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Other Non Operating Income of -$934000.0 for Q4 2025, up 79.88% year-over-year from -$519224.4 in Q4 2024, and up 10.45% quarter-over-quarter from -$1.0 million in Q3 2025.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Other Non Operating Income (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Other Non Operating Income for 13 consecutive years, with -$934000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non Operating Income rose 79.88% year-over-year to -$934000.0; the TTM figure through Dec 2025 stood at $1.0 million (up 120.0% YoY), while the FY2025 annual figure was $1.0 million, up 120.0% from the prior year.
- Other Non Operating Income advanced to -$934000.0 in Q4 2025 per RARE's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $3.1 million in Q3 2024 and bottomed at -$4.6 million in Q4 2024.
- Historically, Other Non Operating Income has averaged -$412650.0 across 5 years, with a median of -$557000.0 in 2021.
- Annual changes were most pronounced in 2022 — Other Non Operating Income plunged 1288.06% — and 2023, when it jumped 666.67%.
- Ultragenyx Pharmaceutical's Other Non Operating Income stood at -$410000.0 in 2021, then jumped by 143.9% to $180000.0 in 2022, then surged by 666.67% to $1.4 million in 2023, then sank by 436.45% to -$4.6 million in 2024, then jumped by 79.88% to -$934000.0 in 2025.
- Business Quant data shows RARE's Other Non Operating Income at -$934000.0 in Q4 2025, -$1.0 million in Q3 2025, and $2.1 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Dec 31, 2025 | -934,000.00 |
| Sep 30, 2025 | -1.04 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 837,000.00 |
| Dec 31, 2024 | -4.64 Mn |
| Sep 30, 2024 | 3.08 Mn |
| Jun 30, 2024 | -1.83 Mn |
| Mar 31, 2024 | -1.61 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | -699,000.00 |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | 308,000.00 |
| Dec 31, 2022 | 180,000.00 |
| Sep 30, 2022 | -1.11 Mn |
| Jun 30, 2022 | -930,000.00 |
| Mar 31, 2022 | 289,000.00 |
| Dec 31, 2021 | -410,000.00 |
| Sep 30, 2021 | -415,000.00 |
| Jun 30, 2021 | -67,000.00 |